Cancer Genome Analysis

Malignant Tumor Clinical Trial

Official title:

Cancer Genome Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01458704
• Other study ID #: Cancer genome analysis
• Status: Recruiting
• Phase: N/A
• First received: October 23, 2011
• Last updated: October 24, 2011
• Start date: August 2011

Study information

• Verified date: October 2011
• Source: Seoul National University Hospital
• Contact: Tae-You Kim
• Phone: 82-2-2072-2228
• Is FDA regulated: No
• Health authority: Republic of Korea: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Next generation sequencing (including targeted gene seqeuncing, exome and transcriptome sequencing) will be performed from fresh frozen tumor samples to understand the genetic alteration of tumors and to aid in optimal selection of further therapeutic agents.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with malignant tumor

• receiving or planning to receive chemotherapy

• with fresh frozen tumor tissue

• with informed consent

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Malignant Tumor
• Neoplasms

Intervention

Other:
• next generation sequencing
next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	targeted sequencing of cancer-relate genes	Identification and characterization of genetic alteration in cancer tissue	1 year	No